The third annual Co-Creating Impact Summit in collaboration with Novartis’ Impact Valuation Advisory Council – chaired by John Elkington – brought together internal and external thought leaders in the area of ESG, sustainability and impact valuation to discuss and debate on the current status, future perspectives and ways Novartis could be best prepared for the future.
The hugely successful event with over 1,100 registrations reflected on the most pressing topics around Investors and Sustainability, Climate and Health, the Future of Integrated Reporting, the Role of Governments, and how to measure, value and manage impact.
Another important element of the Summit was that Novartis announced the renaming of Financial, Environmental and Social (FES) Impact Valuation to Social, Environmental and Economic (SEE) impact valuation to better reflect the significance of social impact to the business while keeping the environment at the center.
Deep dive to the discussions around the various topics by listening to the recording of the sessions.
There is also a fun way to learn more about this Co-Created Impact Summit 2020 by exploring the virtual exhibition (until the end of 2021), which showcases important work and best practices from internal and external practioners in the area of impact valuation and materiality, including:
- Building blocks of our Co-Creating Impact Roadmap
- Inspiring best practices created by internal and external practitioners
- Key publications highlighting relevant external trends
This Summit also highlighted the key role of Impact Valuation. Not to be confused with sustainability reporting, Impact Valuation is an approach that measures and values impact to understand whether society is better or worse off as a result of a company’s operations around the world. Novartis has already been recognized as a pioneer in the field by the Harvard Business School, and has initiated a range of pilot experiments to explore and articulate the value we have across our supply chain.